• Initial dose: Rivastigmine 1.5 mg twice a day.
• Dose titration: The starting dose is Rivastigmine 1.5 mg twice a?day. If this dose is well tolerated after a minimum of two weeks of treatment, the dose?may be increased to Rivastigmine 3 mg twice a day. Subsequent?increases to 4.5 mg and then 6 mg twice a day should also be based on good tolerability?of the current dose and may be considered after a minimum of two weeks of treatment at?that dose level.
• Maintenance dose: The effective dose is 3 mg to 6 mg twice a day; to achieve maximum therapeutic benefit patients should be maintained on their highest well tolerated dose. The recommended maximum?daily dose is 6 mg twice a day. Maintenance treatment can be?continued for as long as a therapeutic benefit for the patient exists.?
• Re-initiation of therapy: If treatment is interrupted for more than several days, it should be re-initiated at 1.5 mg twice daily. Dose titration should then be carried out as described above.

Rivastigmine transdermal patch: Apply patch on intact skin for a 24-hour period; replace with a new patch every 24 hours.

• Initial Dose: Initiate treatment with 4.6 mg/24 hours Rivastigmine transdermal patch.
• Dose Titration: After a minimum of 4 weeks, if tolerated, increase dose to 9.5 mg/24 hours, which is the minimum effective dose. Following a minimum additional 4 weeks, may increase dosage to maximum dosage of 13.3 mg/24 hours.
• Mild to Moderate Alzheimer’s Disease and Parkinson?s Disease Dementia: Rivastigmine transdermal patch 9.5 mg/24 hours or 13.3 mg/24 hours once daily.
• Severe Alzheimer?s Disease: Rivastigmine transdermal patch 13.3 mg/24 hours once daily.
• For treatment interruption longer than 3 days, retitrate dosage starting at 4.6 mg per 24 hours.